| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CLSTN3 |
| Uniprot No | Q9BQT9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 20-847aa |
| 氨基酸序列 | MASMTGGQQMGRGHHHHHHGNLYFQGGEFNKANKHKPWIEAEYQGIVMEN DNTVLLNPPLFALDKDAPLRYAGEICGFRLHGSGVPFEAVILDKATGEGL IRAKEPVDCEAQKEHTFTIQAYDCGEGPDGANTKKSHKATVHVRVNDVNE FAPVFVERLYRAAVTEGKLYDRILRVEAIDGDCSPQYSQICYYEILTPNT PFLIDNDGNIENTEKLQYSGERLYKFTVTAYDCGKKRAADDAEVEIQVKP TCKPSWQGWNKRIEYAPGAGSLALFPGIRLETCDEPLWNIQATIELQTSH VAKGCDRDNYSERALRKLCGAATGEVDLLPMPGPNANWTAGLSVHYSQDS SLIYWFNGTQAVQVPLGGPSGLGSGPQDSLSDHFTLSFWMKHGVTPNKGK KEEETIVCNTVQNEDGFSHYSLTVHGCRIAFLYWPLLESARPVKFLWKLE QVCDDEWHHYALNLEFPTVTLYTDGISFDPALIHDNGLIHPPRREPALMI GACWTEEKNKEKEKGDNSTDTTQGDPLSIHHYFHGYLAGFSVRSGRLESR EVIECLYACREGLDYRDFESLGKGMKVHVNPSQSLLTLEGDDVETFNHAL QHVAYMNTLRFATPGVRPLRLTTAVKCFSEESCVSIPEVEGYVVVLQPDA PQILLSGTAHFARPAVDFEGTNGVPLFPDLQITCSISHQVEAKKDESWQG TVTDTRMSDEIVHNLDGCEISLVGDDLDPERESLLLDTTSLQQRGLELTN TSAYLTIAGVESITVYEEILRQARYRLRHGAALYTRKFRLSCSEMNGRYS SNEFIVEVNVLHSMNRVAHPSHVLSSQQFLHRGHQPPPEMAGHSLASSHR NSMIPSA |
| 预测分子量 | 96 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CLSTN3重组蛋白的参考文献示例(注：部分内容基于领域内相关研究的概括，具体文献需根据实际数据库检索确认)：
1. **文献名称**: "Calsyntenin-3 regulates endosomal recycling and synaptic plasticity via γ-secretase processing"
**作者**: Vagnoni A, et al.
**摘要**: 本研究利用重组CLSTN3蛋白，揭示了其通过γ-分泌酶依赖性切割调控内体运输的机制，并发现其缺失会导致突触可塑性受损，提示其在阿尔茨海默病中的潜在作用。
2. **文献名称**: "Structural insights into CLSTN3-mediated neuronal adhesion"
**作者**: Li Y, et al.
**摘要**: 通过表达纯化重组CLSTN3胞外域蛋白，结合X射线晶体学分析其结构，发现其钙离子依赖性结合特性，并阐明其在神经元间粘附和轴突导向中的功能。
3. **文献名称**: "CLSTN3 interacts with APP and BACE1 to modulate amyloid-β production"
**作者**: Kim S, et al.
**摘要**: 使用重组CLSTN3蛋白进行体外结合实验，证明其与APP和BACE1形成复合物，促进β-淀粉样蛋白生成，为CLSTN3在阿尔茨海默病病理中的角色提供证据。
4. **文献名称**: "Recombinant CLSTN3 as a novel biomarker for early cognitive decline"
**作者**: Wang X, et al.
**摘要**: 开发了基于重组CLSTN3蛋白的血清检测方法，发现其在轻度认知障碍患者中表达异常，提示其作为神经退行性疾病生物标志物的潜力。
**提示**：以上为模拟示例，实际文献需通过PubMed/Google Scholar检索确认。建议使用关键词“CLSTN3 recombinant”“calsyntenin-3 expression”进行精确查找，并关注近5年内的研究以获取最新进展。
**Background of CLSTN3 Recombinant Protein**
CLSTN3 (Calsyntenin-3), a member of the calsyntenin family, is a type I transmembrane protein predominantly expressed in the brain, particularly in neurons. It plays a role in synaptic organization, intracellular transport, and cell adhesion. Structurally, CLSTN3 contains two extracellular cadherin-like domains, a conserved cytoplasmic domain, and a short intracellular tail. Its interaction with kinesin motors facilitates vesicle trafficking along microtubules, influencing neurotransmitter release and receptor localization. Dysregulation of CLSTN3 has been linked to neurodevelopmental disorders and neurodegenerative diseases, including Alzheimer’s disease, where it may affect amyloid precursor protein (APP) processing.
Recombinant CLSTN3 protein is engineered using heterologous expression systems (e.g., mammalian, insect, or bacterial cells) to produce purified, functional protein for research. This enables studies on its biochemical properties, ligand-receptor interactions, and role in signaling pathways. Tagged versions (e.g., His-, Fc-, or GFP-tagged) are commonly generated to simplify purification and detection. Researchers utilize recombinant CLSTN3 to explore its involvement in synaptic plasticity, neuronal connectivity, and disease mechanisms, offering insights into therapeutic targeting. Its application spans *in vitro* binding assays, structural studies, and cell-based models to decipher pathological pathways or validate drug candidates.
×
